Transmission from vaccinated hosts can cause dose-dependent reduction in pathogen

virulence

Short title: Vaccination and the transmission of pathogen virulence.

Richard I. Bailey[1]*, Hans H. Cheng[2], Margo Chase-Topping[1,3], Jody K. Mays[2], Osvaldo

Anacleto[1,4], John R. Dunn[2]† and Andrea Doeschl-Wilson[1]†

Affiliations:

[1]Division of Genetics and Genomics, The Roslin Institute, Easter Bush, Midlothian, UK.

[2]USDA, Agricultural Research Service, US National Poultry Research Center, Avian Disease

and Oncology Laboratory, East Lansing, MI 48823, USA.

[3]Usher Institute of Population Health Sciences & Informatics, University of Edinburgh,

Edinburgh, UK.

[4]Current address: Institute of Mathematical and Computer Sciences, University of São Paulo,

São Carlos, Brazil.

*Corresponding author. Email: r.bailey@ed.ac.uk

†Joint senior authors.

Abstract

Many livestock and human vaccines are leaky as they block symptoms but do not

prevent infection or onward transmission. This leakiness is concerning as it increases

vaccination coverage required to prevent disease spread, and can promote evolution of

increased pathogen virulence. Despite leakiness, vaccination may reduce pathogen load,

affecting disease transmission dynamics. However, the impacts on post-transmission

disease development and infectiousness in contact individuals are unknown. Here, we

use transmission experiments involving Marek's disease virus in chickens to show that

vaccination with a leaky vaccine substantially reduces viral load in both vaccinated

individuals and unvaccinated contact individuals they infect. Consequently, contact

birds are less likely to develop disease symptoms or die, show less severe symptoms, and

shed less infectious virus themselves, when infected by vaccinated birds. These results

highlight that even partial vaccination with a leaky vaccine can have unforeseen positive

consequences in controlling the spread and symptoms of disease.

Introduction

Vaccination is routinely used as an efficient and economical way to control the spread and symptoms of infectious diseases in humans and livestock. Vaccines vary in their protective properties[1,2], and while some completely block infection, others only prevent disease symptoms but not infection or onward transmission. The latter are termed 'leaky' or 'imperfect' vaccines. Leaky vaccines are commonly used to prevent or alleviate disease symptoms in livestock, and are becoming more prevalent among human vaccines[3]. Leakiness allows pathogen populations to persist even at high levels of vaccination coverage[4], and reduced mortality of vaccinated individuals can lengthen their infectious period and hence promote the evolution of increased pathogen virulence[5]. A better understanding of the overall impacts on populations of vaccination with leaky vaccines is therefore urgently needed.

The underlying hypothesis in this paper is that vaccination, even with leaky vaccines, not only has direct positive effects on vaccinated individuals, but also indirect positive effects on individuals in the same contact group. Often only a fraction of a population receives the direct benefits of vaccination, due to incomplete coverage and heterogeneity in vaccine responses[15-17]. However, vaccination even with a leaky vaccine often reduces pathogen load in infected individuals[5-12], with potential consequent reduction in the exposure dose of susceptible individuals. Transmission experiments, in which infected 'shedders' are placed in contact with uninfected 'contact' individuals and transmission recorded, have revealed that lower shedder pathogen load reduces transmission in some cases[5,13-14], but not all[10]. Measures of vaccine effectiveness can include these indirect benefits for unvaccinated individuals, through dose-dependent reduction in transmission rates from infected vaccinated individuals[18]. However, beyond transmission effects, lower exposure dose can also decrease pathogen load in newly infected hosts[19-21], potentially leading to decreased pathogen

virulence[19-20,22-27] and infectiousness in these secondary cases. These downstream effects of

leaky vaccines on disease development and spread are currently poorly understood. Here, we

use transmission experiments with vaccinated versus sham-vaccinated shedders and only

unvaccinated contact individuals, to examine how a leaky vaccine affects both transmission

and subsequent pathogen virulence and load (and hence, potentially, infectiousness) in

contacts.

Gallid alphaherpesvirus 2, more commonly referred to as Marek's disease virus (MDV), is a

highly oncogenic herpesvirus of poultry causing worldwide annual losses of 1-2 billion

USD[28]. It is an airborne pathogen, spreading via inhalation of virus-laden "chicken dust",

which accumulates through shedding of infectious feather follicle epithelia[29]. Marek's disease

(MD) symptoms include peripheral nerve enlargement, tumours in a variety of organs, wing

and leg paralysis, and iris lymphoma causing pupil irregularities, as well as death. Infected

birds remain infectious for life, and the virus can remain viable in the environment for many

months. Higher MDV ingestion dose has been reported to increase disease progression[27,30],

but has not been linked to vaccination or exposure dose under natural transmission. On top of

clear welfare concerns, MD causes production losses at inspection due to a drop in egg

production of laying hens[31], and symptoms known as "leukosis" leading to meat

condemnation. Leukosis has other causative agents but is primarily due to MDV in

chickens[32].

Management of MD led to development of the first widely-used anti-cancer vaccine, the

related live turkey herpesvirus *Meleagrid alphaherpesvirus 1*, commonly referred to as

HVT[33]. In the US, vaccination of all commercial poultry has been routine since the 1970s.

However, from the 1950s to the present day there have been several jumps in MDV

virulence[34], each causing more severe symptoms and reducing the symptom-blocking effects

of existing vaccines. Several generations of vaccines have been developed to combat this

increased virulence, all of which are leaky and may in fact have contributed to continuing

virulence evolution[5]. Currently, widespread vaccination leads to low production losses in the

US commercial poultry industry. However, vaccination is not routine worldwide, and may

vary considerably in quantity and quality[35], leading to incomplete effective vaccine coverage

within a flock.

High variability in virulence among MDV strains[36], in genetic resistance among chicken

strains[37], and in vaccine effectiveness[38], combined with well-developed empirical methods

for examining host infection and disease[39], make MDV in chickens an ideal model system to

examine the relationships between vaccination with leaky vaccines and pathogen load,

transmission, and subsequent virulence in non-vaccinated birds.

The overall aim of this study was to assess how vaccination with a leaky vaccine affects

pathogen transmission and subsequent disease development in unvaccinated contact

individuals. To investigate this, we carried out transmission experiments for MDV in

chickens, where vaccinated or sham-vaccinated shedder birds inoculated with MDV were

placed in contact with unvaccinated naïve contact birds (Fig 1). We chose unvaccinated

contacts to avoid confounding effects of vaccination on contact bird resistance and shedder

transmission ability. We investigated to what extent vaccination reduces both MDV

transmission and subsequent disease severity in contacts, and asked whether the effects of

shedder vaccination on contacts were mediated by lower shedder viral load. We found that

shedder vaccination led to a large reduction in contact disease symptoms, and confirmed that

this effect was mediated by viral load.

Fig 1. Schematic overview of one "lot" (2 lots per replicate, one for each shedder vaccination

status) of the MD transmission experiment. In each lot, shedder birds were all either HVT-

vaccinated or PBS sham-vaccinated. All contacts were unvaccinated. The experiment comprised 16

replicates, each consisting of one lot in which three infected vaccinated shedders were placed in 48

hour contact with 15 naïve unvaccinated contacts at 2 time points, and one equivalent lot with sham-

vaccinated shedders (4 additional sham-vaccinated lots were added as two of these had only 2

shedders due to early death). In total, there were thus 1080 contacts and 106 shedder individuals

distributed into 72 contact bird groups. Contact bird groups each had roughly equal numbers of males

and females. All indicated time points (not to scale) are relative to the day of shedder inoculation with

wild-type virus. Open and closed symbols represent uninfected and infected chickens, respectively.

For all birds, necropsy was carried out to determine the presence and severity of disease symptoms

(tumours and peripheral nerve enlargement) at 8 weeks post-infection (shedders) or post-contact

(contact birds), or upon death/euthanasia, whichever was the sooner.

Results

Establishing the transmission model and sampling times. Given the novelty of the

experimental setup, appropriate contact duration and sampling times to examine shedder

vaccination effects needed to be established in pilot experiments prior to the main trial. Pilot

experiment methods and results are presented in Supplementary Information. As little as 4

hours of contact between inoculated shedders and uninfected contacts was sufficient for most

contact birds to become infected and show visible disease symptoms by 8 weeks post-contact

(Fig S1). A contact duration of 2 days was subsequently chosen to ensure ample shedding

time and to standardize time available for shedding of feather follicle epithelia by the

shedders. Both vaccinated and sham-vaccinated shedders were positive for small quantities of

virus in feather follicle epithelia by 7 days post-infection (hereafter DPI), but this feather

viral load (hereafter FVL) had increased considerably by 10-12 DPI (Fig S2). When shedders

were moved to a new set of contacts every 2 days from 10-20 DPI, the proportion of infected

contacts, as measured by qPCR from feather and blood samples collected 14 days post-

contact (hereafter DPC), was consistently high (Fig S3). However, while contact with sham-

vaccinated shedders also consistently led to high incidence of disease symptoms at necropsy,

contact with vaccinated shedders led to lower proportion of diseased contacts, in particular at

the early contact periods. These temporal trends coincided with differences in shedder FVL,

with higher overall FVL in sham-vaccinated birds, reaching a peak around 12 DPI, and lower

FVL peaking around 20 DPI in vaccinated shedders (see Fig S2). Both groups of shedders

then remained positive for virus in feathers for the 8-week duration.

Informed by the pilot data, we chose 13 and 20 shedder DPI as standardized contact start

times in the main experiments (Fig 1) to capture the aforementioned temporal variation in

vaccine effects, and a 2-day contact period between shedders and contacts. Fourteen DPC

152 was chosen as the time for contact bird blood and feather sampling, as it proved ample for

153 build-up of FVL in infected contacts while minimizing among-contact transmission (Fig S4).

154 Viral loads were highly correlated between blood and feathers (main experiment contact

155 birds only, correlation coefficient r = 0.73) and were typically higher and more often above

156 the detection threshold in feathers, as shown previously[40]. Hence, we focused on viral load in

157 feathers for all analyses, due to the dual benefits of the typically above-threshold level viral

158 loads and the fact that feathers are the infectious tissue, hence increasing the likely

159 association with infectiousness. Examination of the presence and severity of disease

160 symptoms (tumours and peripheral nerve enlargement) at necropsy took place at 8 weeks

161 post-infection (shedders) or post-contact (contacts), or when moribund, if this occurred

162 earlier. The subsequent results only refer to analyses of data from the main experiment

163 illustrated in Fig 1.

165 **Vaccination blocks shedder disease symptoms without blocking infection**. As expected,

166 all shedder birds were positive for MDV as determined by qPCR, and vaccination almost

167 universally blocked the development of disease symptoms at necropsy. Eighty out of 86

168 sham-vaccinated shedders (93%; 4 out of 90 birds excluded due to early death from other

169 causes) were MD-positive at necropsy, while only 5 out of 80 (6%) vaccinated shedders were

170 MD-positive.

172 **Shedder vaccination does not block transmission but reduces contact bird disease**

173 **development and pathogen load**. The complete set of contact bird analysis results are

174 presented in Table S1 (Supplementary Information). Overall, vaccination of shedders did not

175 block virus transmission, but dramatically reduced the negative impacts of infection in

176 contact birds. Almost all contacts became infected regardless of shedder vaccination status or

DPI, with 100% (all 572 birds) contact bird infection for sham-vaccinated shedders and

97.4% for vaccinated (442 out of 454). This difference, albeit small, was significant, with

contacts of sham-vaccinated shedders 0-0.28 times as likely to remain uninfected as contacts

of vaccinated (Fisher exact test: 16.82, p<0.001, odds ratio = 0, 95% C. I. 0, 0.28). However,

fewer infected contacts developed visible disease symptoms or died within 8 weeks (Fig 2a),

and of those showing visible symptoms, shedder vaccination was associated with less severe

contact bird symptoms, including fewer tissues with tumours and less severe enlargement of

peripheral nerves, as illustrated by non-metric multidimensional scaling (Fig 2b).

Fig 2. Summary of shedder impacts on contact birds. (A) Impact of shedder vaccination status on

contacts at 13 and 20 shedder DPI. Contacts positive for virus in qPCR from samples taken at 14

DPC were classified as infected. "Diseased" individuals showed visible symptoms (peripheral nerve

enlargement and/or tumours) at necropsy, 8 weeks post contact or upon death. "Dead" contacts were

those that died or were humanely euthanized before the end of the 8-week experimental period, were

infected, and were positive for disease symptoms at necropsy. HVT = vaccinated shedders; PBS =

sham-vaccinated shedders. (B) Non-metric multidimensional scaling plot, for diseased contacts only,

of relationships between contact bird disease severity (number of tissues with tumours; VNE = vagus

nerve enlargement; SNE = sciatic nerve enlargement; BNE = brachial nerve enlargement), contact

bird sex, and shedder vaccination status and FVL. Points are individual contact birds. Arrow distance

along each axis represents its nonparametric Kendall's tau correlation with that axis. Variables differ

qualitatively (binary, continuous or ordinal) and so correlation coefficients and hence arrow lengths

may not be directly comparable. Shedder DPI effects not shown (see Results text and Table S1).

Infected contacts were much less likely to show visible disease symptoms at necropsy after

contact with vaccinated (232 out of 437 contacts; 53%) than sham-vaccinated (558 out of

569; 98%) shedders (Table 1). Disease symptoms in infected contacts were also more likely

in the 20 DPI than 13 DPI contact groups (mixed-model logistic regression: z = 4.5, p <

0.0001), but this temporal effect was smaller when shedders were sham-vaccinated

(vaccination status by DPI interaction; z = -2.3, p < 0.05). Males were marginally less likely

to show visible disease symptoms than females (z = -1.9, p = 0.05).

Table 1 | Effects of shedder vaccination status on contact bird disease symptoms, mortality and feather viral load for a model also including contact bird sex and shedder DPI, but excluding DPI by vaccination status interaction. Full results, including models with the interaction, are in Table S1.

Contact bird response	Shedder vaccination coefficient (SE)[6]	Test statistic[7]	p value
Disease status[1]	8.19 (1.50)	5.45	< 0.0001 ***
Mortality[2]	1.74 (0.20)	8.76	< 0.0001 ***
N tissues with tumours[3]	0.50 (0.13)	3.71	< 0.0005 ***
Vagus nerve enlargement[4]	0.22 (0.23)	0.94	0.35
Brachial nerve enlargement[4]	1.30 (0.26)	5.01	< 0.0001 ***
Sciatic nerve enlargement[4]	1.30 (0.24)	5.36	< 0.0001 ***
Feather viral load[5]	1.98 (0.11)	18.3	< 0.0001 ***

[1]Infected contacts (qPCR) only. Logistic regression. Coefficient = mean log odds ratio for presence of contact disease symptoms when exposed to sham-vaccinated relative to vaccinated shedders.

[2]Infected contacts (qPCR) only. Cox proportional hazards. Coefficient = log hazard ratio of contact death at a given time point associated with sham-vaccinated relative to vaccinated shedders.

[3]Diseased contacts (necropsy) only. Poisson GLM. Coefficient = mean difference in number of contact tissues containing tumours with sham-vaccination.

[4]Diseased contacts (necropsy) only. Ordinal logistic regression. Coefficient = proportional log odds of an increase in contact nerve enlargement ranking with sham-vaccination.

[5]All contacts. Least square mean difference in contact bird $\log_{10}$(viral load + 1e-5) with sham-vaccinated relative to vaccinated shedders.

[6]Positive = increase in contacts when exposed to sham-vaccinated relative to vaccinated shedders, except for Feather viral load (> 1 = increase with sham-vaccination).

[7]t statistic for linear regression, z statistic for all other models.

Mortality rates were also much lower among infected contacts exposed to vaccinated

shedders (Fig 3), with those exposed to sham-vaccinated shedders being 6 times more likely

to die per unit time (95% C. I. 3.9, 8.4; Table 1). Controlling for vaccination effects, contacts

exposed to shedders at 20 DPI were almost twice as likely to die as those exposed to shedders

at 13 DPI (95% C. I. 1.3, 2.1; z = 3.6, p < 0.0005).

Fig 3. Cox proportional hazards estimated survival probability curves for all combinations of

shedder vaccination status and days post-inoculation (DPI). Shaded areas represent 95%

confidence intervals. HVT = vaccinated shedders; PBS = sham-vaccinated shedders. Note that all

mortality up to 7 days post contact (DPC) was assumed to be chick mortality unrelated to MD, and

these individuals were excluded from all analyses.

Among contacts positive for disease symptoms at necropsy, shedder vaccination led to

significantly lower disease severity (number of tissues with tumours, and enlargement of 3

peripheral nerves; see Fig 2b) for all individual symptoms except vagal nerve enlargement

(Table 1). There was no evidence for an increase in contact bird disease severity between

shedder DPI 13 and 20 for either vagus nerve (mixed-model ordinal logistic regression: z = -

0.1, p = 0.89) or tumours (z = 1.2, p = 0.21), but marginal evidence for greater brachial nerve

enlargement (z = 1.9, p = 0.06) and a significant increase in sciatic nerve enlargement (z =

3.1, p < 0.005) associated with the later exposure time. Regardless of the shedder vaccination

status and exposure time, disease severity was significantly higher in contact females than

males for all symptoms (Fig 2b; Table S1).

Next, we tested the extent to which shedder vaccination status also influenced contact FVL as

an indicator of the infectiousness of contact birds, which has potentially important knock-on

effects for epidemiological dynamics. Infectiousness is likely to be determined by the amount

of virus shed into the environment. Across all individuals, contact bird FVL at 14 DPC was

much higher when exposed to sham-vaccinated than vaccinated shedders (Table 1, Fig 4).

Contact FVL was also higher when exposed to shedders at 20 DPI than 13 DPI (mixed-model

linear regression: t = 4.9, p < 0.0001).

Fig 4. Box and whisker plot of shedder and contact feather viral loads at 13 and 20 DPI.

Horizontal bars are medians. Boxes cover the 1st to 3rd quartile, and vertical lines extend to maxima

and minima except in the presence of outliers (filled circles). Shedder feather samples were taken at

the start of each contact period, contact samples at 14 DPC. A small value (1e-5) was added to

feather viral load values prior to log transformation, and hence the $\log_{10}$(viral load) for birds negative

for virus was -5.

In summary, contact birds exposed to vaccinated shedders still became infected, but were

considerably less likely to develop disease, experienced milder symptoms and lower

mortality, and had lower feather viral loads.

Shedder vaccination effects on contacts are mediated by feather viral load. We

hypothesized that the effects of shedder vaccination on contacts, described above, were

mediated by a reduction in shedder FVL with vaccination, leading to a reduction in contact

exposure dose with knock-on effects for disease development. To test this hypothesis, we

followed the protocol for mediation analysis using regression, outlined in the Statistical

Analysis section of the Methods.

Sham-vaccinated shedders had much higher FVL than vaccinated (mixed-model linear

regression: t = 13.35, p < 0.0001; Fig 4). There was a highly significant increase in shedder

FVL at 20 DPI over 13 DPI (t = 7.49, p < 0.0001), but the highly significant interaction

between vaccination status and DPI (t = -5.03, p < 0.0001) revealed that this temporal change

only occurred in vaccinated shedders.

Replacing shedder vaccination status with shedder FVL as a covariate in the statistical

models for contact birds, revealed that the effects of shedder FVL on contacts followed the

same pattern as the effects of shedder vaccination status. Higher shedder FVL led to a small

but significant increase in contact bird infection probability (univariate logistic regression:

log odds = 0.76, z = 3.0, p < 0.005), with predicted infection probability increasing from

0.946 at the lowest shedder FVL values to 0.997 at the highest. Higher shedder FVL led to

greater contact bird disease prevalence and severity, greater mortality, and higher contact

FVL (Table 2).

Table 2 | Effects of shedder feather viral load on contact bird disease symptoms and feather viral load, for a model also including contact sex and shedder DPI, but not including shedder vaccination status. Full results in Table S1.

Contact bird response	Shedder viral load slope (SE)	Test statistic[6]	p value
Disease status[1]	3.83 (0.62)	6.17	< 0.0001 ***
Mortality[2]	0.93 (0.11)	8.76	< 0.0001 ***
N tissues with tumours[3]	0.34 (0.09)	3.57	< 0.0005 ***
Vagus nerve[4]	0.24 (0.16)	1.51	0.13
Brachial nerve[4]	0.91 (0.17)	5.4	< 0.0001 ***
Sciatic nerve[4]	0.90 (0.16)	5.57	< 0.0001 ***
Feather viral load[5]	0.83 (0.08)	10.33	< 0.0001 ***

Including shedder FVL in a model alongside vaccination status reduced, but did not always

remove, the significance of vaccination status for all contact bird disease variables (Table

S1). This indicated that shedder FVL at least partially explained the impacts of shedder

vaccination on infected contacts. However, the further addition of contact FVL and sum of

contact groupmate FVL (the latter to account for possible among-contact infection during the

8-week experimental period) as predictors fully explained the effects of shedder vaccination

on contact disease and survival, rendering shedder vaccination status non-significant in all

models (Fig 5). The results imply that shedder vaccination effects on contacts are fully

mediated by FVL of shedders and infected contacts.

Fig 5. Diagrammatic representation of the mediating effects of viral load on contact bird binary

disease status. Each arrow colour represents a different multiple regression analysis, with arrows

pointing from predictors to response. Arrow thickness represents regression coefficient (all significant

or marginal relationships were positive). The diagram shows that the effect of shedder FVL on contact

FVL (see Table 2) fails to fully explain the shedder vaccination effect, which remains significant when

both variables are included (purple arrows). The same is true for the cumulative FVL of all infected

group-mates (yellow arrows). However, the three FVL predictor variables completely remove the

effect of shedder vaccination status (blue arrows) in explaining contact disease status (see Table 1),

and this is true for all other contact disease variables (Table S1). This implies that shedder

vaccination effects on contacts are fully mediated by FVL of infected individuals in a contact group.

Significance is indicated by asterisks: *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$, ns = not significant.

Marginally non-significant p-values are presented numerically. All results presented here are from

models excluding the DPI by vaccination status interaction, but including sex and DPI main effects

(not shown, see Table S1).

Discussion

We used controlled experiments involving natural virus transmission to reveal that vaccination with a leaky vaccine, which only marginally reduces transmission, can significantly reduce post-transmission disease development and mortality among unvaccinated contact individuals. Our analysis confirms that this effect is mediated by a reduction in exposure dose experienced by susceptible individuals when exposed to vaccinated shedders, leading to lower pathogen load and concomitant reduced symptoms in contact birds. The primary objectives of vaccination of livestock with leaky vaccines are to improve animal welfare and to reduce production losses caused by disease symptom development. Our results show that even partial vaccination against MD can substantially reduce disease symptoms and mortality in the whole flock, leading to universally positive impacts on animal welfare and productivity, and these conclusions may extend to leaky vaccines used in other systems.

One of the key findings of this study was that shedder vaccination effects on MD symptom prevalence and subsequent mortality within each contact group were fully explained by the cumulative FVL of all infected group members, measured at a relatively early stage of the epidemic, prior to onset of contact-contact transmission. This would suggest that contacts exposed to vaccinated shedders experienced overall lower cumulative exposure dose, including from other infected contacts, over the course of 8 weeks, resulting in milder symptoms and lower mortality. This negative feedback on the environmental pathogen burden strongly advocates the application of MD intervention strategies that reduce either within-host or environmental virus load, even if only moderately[41]. In general, depending on the relationship between exposure dose and subsequent within-host replication in any

particular system, targeting reduction in pathogen load in intervention strategies may have

greater positive knock-on effects than currently assumed.

Increased disease severity with higher virus inoculation dose has been shown previously for

MD in chickens[27,30], but not with natural transmission and not linked to interventions such as

vaccination. The route of infection is known to alter the extent of infection and number of

diseased tissues[42], hence it is important to mimic the field situation closely in order to

accurately predict the outcome of vaccination and other intervention strategies in this and

other systems. It is also important to measure pathogen load specifically in the infectious

tissues where possible, or to measure shedding directly, as tissues may differ in the strength

of association between their pathogen load and infectiousness. Vaccine experiments routinely

establish the protective effect of vaccination on infection or disease progression, and

pathogen shedding, in vaccinated individuals themselves[43], and occasionally also examine

onward transmission. The novelty and primary focus of this study was to determine the

effects of vaccination of 'shedder' individuals on disease progression and infectiousness

specifically in newly infected, unvaccinated, contact individuals. To date, little is known

about these potential 'downstream' effects of vaccination, and the majority of

epidemiological models that predict the consequences of vaccination on disease spread and

pathogen evolution assume that these don't exist[3,44]. Our findings that vaccination affects

downstream pathogen load and host survival and hence, potentially, onward pathogen

transmission, in a dose-dependent manner may have profound consequences for such

predictions. Particularly in systems where an individual's infectiousness is strongly

influenced by its pathogen load, existing estimates of the required vaccine coverage for

achieving so-called herd immunity, i.e. for preventing disease spread within a population,

may be upwardly biased. Based on current estimates, herd immunity is assumed to require

high coverage when vaccines are leaky[18,45]. Complete vaccine coverage is not typical for all

infectious diseases throughout the world, and even where it is routine, vaccine administration

can vary in quality. Furthermore, high variation in vaccine responsiveness may render a

significant proportion of vaccinated animals effectively non-immunized[46]. The results of our

study suggest that partial vaccination or high prevalence of vaccine non-responders may

impose less risk with respect to disease invasion and persistence than anticipated from

existing theory[4,47-48]. Prediction of the coverage required for herd immunity would benefit

from an understanding of the downstream effects of vaccination-induced changes in exposure

dose and their effects on individuals' infectiousness and survival in any particular system.

These insights would also be useful for the development of dynamic epidemiological models

that incorporate dose-dependent transmission effects and the impact of interventions on

these[19,24,49-51].

Vaccination with leaky vaccines has been implicated in the evolution of increased pathogen

virulence, primarily because vaccination reduces host mortality without preventing disease

spread, allowing infectious hosts more time to transmit virulent pathogen strains[3,5,44]. The

best evidence for this effect comes from studies of MDV[5]. Our results, showing that

vaccination reduces negative impacts of MD by lowering pathogen load, do not contradict

this hypothesis. However, the existence of vaccine-induced downstream effects of exposure

dose on host infectiousness, recovery and survival, is likely to alter the strength of selection

favouring more virulent strains. Furthermore, the lower pathogen load and slightly reduced

rate of spread revealed here – the latter effect potentially being stronger in other systems -

would lower the effective population size of the virus, therefore lowering the probability of

establishment and fixation of new beneficial mutations such as those increasing virulence[52].

This may partially explain why years pass between reported increases in MDV virulence,

despite 59 billion chickens being reared annually worldwide[34,53]. The results of this study

therefore suggest that existing models of virulence evolution would benefit from

incorporation of dose response effects on downstream disease severity and mortality such as

those detected here.

Vaccination is often not the only available intervention technique, and others such as

improved animal husbandry techniques or genomic selection of genetically more resistant

individuals[54-56] may also be available and cost-effective. The mediating effect of pathogen

load can be used as a link for comparison between the effects of different interventions on

pathogen dynamics and disease severity. Chickens are known to vary genetically in their

resistance to MD[54], and hence a next step in understanding the benefits of interventions in

this system would be to compare vaccination effects with host genetic effects. Furthermore,

more virulent virus strains tend to result in higher viral shedding rates and may differ in their

response to vaccination[5]. Hence, future studies to test the validity of our findings for multiple

MDV and vaccine strains are warranted.

With the increasing development of leaky vaccines for treatment of human as well as

livestock infectious diseases[3], there is great benefit in improving prediction of their

consequences for host welfare, pathogen dynamics and virulence evolution. The currently

neglected downstream, post-transmission effects that were revealed in this study are likely to

impact all of these important facets of infectious disease biology, and hence disease

management strategies. They therefore merit greater attention in future vaccine-related

studies.

Methods

Transmission experiments. Experiments were carried out at USDA, ARS, USNPRC, Avian

Disease and Oncology Laboratory (ADOL), East Lansing, USA, during 2018. All

experiments used $15I_5$ x 7_1 white leghorn chickens, a F1 hybrid cross of MD-susceptible 15I5

males and 7_1 females[57]. These maternal antibody-negative chickens were reared from a SPF

breeding flock housed in isolators that have received no MD vaccination or exposure. The

flock was negative for MDV antibodies and also for exogenous avian leukosis virus and

reticuloendotheliosis virus, as established by routine surveillance testing. All bird

experiments were approved by the ADOL Animal Care and Use Committee and were carried

out in negative pressure Horsfall-Bauer isolators. Birds were monitored at least daily

throughout the experiment and were humanely euthanized upon reaching established humane

endpoint criteria.

The experiments involved two types of shedders, with shedder birds either vaccinated at

hatch via intra-abdominal (IA) inoculation with 2,000 PFU of HVT (*Meleagrid*

alphaherpesvirus 1)[33], or sham-vaccinated with PBS (phosphate-buffered saline). Each

shedder bird was then challenged with 500 PFU of virulent MDV (strain JM/102W) at 5 days

post-vaccination (0 DPI). Each contact group of birds within each replicate consisted of 3

shedder birds of the same vaccination treatment (HVT or PBS) to be placed in contact with

15 unvaccinated, uninfected contacts (Fig 1). The 3 shedders were placed with the first group

of 15 uninfected contacts at 13 DPI for 48 hours, before being removed back to their isolator

at 15 DPI. They were then placed with a second group of 15 contacts at 20 DPI until 22 DPI.

Contact chicks were hatched weekly so that all contact birds were within 4 days of age when

shedders were first introduced. There were 16 replicates consisting of paired lots of shedder

birds (one lot with 3 vaccinated shedders put into contact with 15 contacts at the two time

points, and the other with 3 sham-vaccinated shedders), and 4 further sham-vaccinated only

replicates. These additional replicates were carried out due to early death of 2 sham-

vaccinated shedders involved in the earlier replicates.

Shedders were then monitored until 8 weeks post-infection and contacts until 8 weeks post-

contact, and mortality (death or euthanasia) recorded. Necropsy was carried out at 8 weeks or

upon death, whichever was the sooner, to determine the presence and severity of MD

symptoms.

Blood (100 μl) and primary feather samples were taken from shedders at the start of each

contact period (13 and 20 DPI) and from contacts at 14 DPC. Based on earlier experiments,

14 DPC was sufficient for build-up of virus in blood and feathers but early enough to avoid

cross-contamination from other contact birds (Supplementary Information). DNA samples

isolated from feather pulp and peripheral blood lymphocytes (PBLs) were used for qPCR to

determine virus load. Each measurement was taken from a unique sample.

DNA from each tissue type was isolated using the Puregene DNA isolation kit (Gentra

System, Minneapolis, MN) followed by a multiplex PCR using methods as previously

described[58]. The TaqMan assay used FAM-TAM probes for MDV gB and VIC-TAM probes

for the cellular GAPDH. Results were reported as the ratio of MDV gB copies per GAPDH

copies, estimated using standard curves consisting of 10- fold serial dilutions of plasmids

containing either MDV gB or GAPDH. Amplifications were performed at Michigan State

University, USA, using the ABI Quant Studio 7Flex BI 7500.

Statistical analyses. Forty-two of 1080 contacts were removed from the dataset prior to

analysis due to chick mortality (death up to 7 days old), with some further filtering for data

quality and death by other causes. Final sample sizes were 211 (shedder FVL as response),

1005 (infected contacts only), 789 (diseased contacts only) and 1023 (all contacts regardless

of infection or disease status). The transmission experiments were analysed using various

linear and generalized linear mixed models in R 3.6.0[59], depending on the type of the

response variable (Table 3). Regression analyses followed the logic of process analysis[63] to

assess the role of pathogen load in mediating shedder vaccination effects on contacts, details

below. Non-metric multidimensional scaling for Fig 2b was carried out in PC-ORD v. 7.0[64]

statistical software. All statistical tests were two-sided. No adjustments were made for

multiple comparisons.

Table 3 | Summary of modelled response variables.					
Response variable	Description	Source	Coefficient interpretation	Statistical model	Data subset[6]
Disease status	Binary presence/absence of visible disease symptoms	Necropsy	Log odds	Logistic regression (GLM binomial errors)[1]	Infected
Mortality	Day of death/euthanasia or last day of study	Daily observations	Log proportional hazard ratio	Right-censored Cox proportional hazards[2]	Infected
N tissues with tumours	Number of tissues with visible tumours	Necropsy	Log relative risk	GLM Poisson errors[3]	Diseased

Nerve enlargement	Qualitative ranking of nerve enlargement (0-4)	Necropsy	Log proportional odds	Ordinal logistic regression[4]	Diseased
Viral load	$\log_{10}$(Ratio of virus to GAPDH quantity + 1e-5)	qPCR	Mean relative quantity	Ordinary linear regression[5]	All

[1] R function glmer in lme4 package[60]; logit link.

[2] R function coxph in survival package[61].

[3] R function glmer in lme4 package; log link.

[4] R function clmm in ordinal package[62]; logit link.

[5] R function lmer in lme4 package; identity link.

[6] Infected = positive for virus in qPCR of one or both of feather and blood samples; Diseased = presence of visible disease symptoms (tumours and/or peripheral nerve enlargement) at necropsy; All = all contact individuals including uninfected.

First, we tested the direct treatment effect (shedder vaccination status) on the outcome

variables (contact disease variables, Table 3). The model formulae also included as fixed

effects contact bird sex and shedder DPI, and a vaccination status by DPI interaction, which

was removed if non-significant. Replicate, and contact group nested within replicate, were

included as random effects in all models except for the survival analysis, for which contact

group and replicate were included as clustering variables. Each contact individual was treated

as a data point. For this and all subsequent analyses, testing contact feather viral load (FVL)

as response involved all contact individuals, infected or uninfected (Table 3). Contact binary

disease status and mortality analyses involved infected (from qPCR) contacts only, and

disease severity variables (tumours and nerve enlargement) involved diseased (from

necropsy) contacts only.

Second, we carried out a mediation analysis, for which we tested all intermediate steps in the

following proposed causal chain (see Fig 5): we hypothesized that the impacts of shedder

vaccination status on the various contact infection and disease variables were primarily

mediated by the vaccine effect on shedder feather viral load (FVL). More specifically we

hypothesized that shedder vaccination directly reduces shedder FVL and consequently also

the exposure dose of contacts. The resulting lower exposure dose may reduce the probability

of becoming infected and/or may lead to lower ingestion dose, and consequently also to

lower viral load in infected contacts. Lower contact viral load reduces the probability in

infected contacts of developing visible disease symptoms or dying within the 8-week

experimental period, and also reduces disease severity among individuals positive for

symptoms at necropsy. Eight weeks is also sufficient time for infected contacts to become

infectious themselves, and for disease development to occur in contacts infected by other

contacts. Hence it was necessary to also consider the FVL of infected group mates alongside

shedder and contact FVL in the mediation analysis.

We began the mediation analysis by testing whether shedder FVL explained a similar amount

of contact bird disease variation as shedder vaccination status, by replacing shedder

vaccination status with shedder FVL in the model formula described in the first step above.

We then tested to what extent shedder FVL was affected by vaccination, and then to what

extent contact FVL and the sum FVL of each contact bird's groupmates (hereafter denoted as

groupmate FVL) were affected by vaccination and shedder FVL. Thus, for contact FVL and

groupmate FVL as response variables, the model formulae were the same as described in the

first step above, with the addition of sum of shedder FVL for each contact group as a fixed

effect. Conversely, when shedder FVL was tested as a response variable, we used each

individual shedder feather sample as a data point, and hence there were two data points per

shedder individual (13 and 20 DPI). For this test we used the same fixed effects model

formula as described in the first step, above, while replicate and shedder individual were

included as random effects, the latter to account for repeated measures.

The values for contact FVL at 14 DPC were calculated as $\log_{10}$(contact FVL + 1e-5) for each

individual. The contact groupmate FVL variable was the sum of FVL at 14 DPC of all 15

contacts in a group, minus the value for the focal individual. This variable was also analysed

as $\log_{10}$(groupmate FVL + 1e-5). For shedder FVL as a predictor, we calculated

$\log_{10}$(sum(shedder FVL + 1e-5)) across the 3 shedders, from feather samples collected at the

start of the contact period with each group of 15 contacts (13 and 20 DPI).

Third and finally, we tested whether shedder vaccination status exerted any effect on contact

disease variables when controlling for mediating effects (shedder, contact, and contact

groupmate FVL). If shedder vaccination status were to be rendered non-significant when

tested alongside FVL variables, this would support the hypothesis that shedder vaccination

impacts on contact disease were fully mediated by their effects on FVL. We first added

shedder FVL alone to the basic model described in step 1, above, to test whether this variable

was an effective bioindicator of shedder vaccination effects in secondary cases (infected

contacts). We then further added contact and groupmate FVL to the model. Same-individual

viral load is expected to be the strongest indicator of disease status, and so we expected

shedder vaccination status and shedder and groupmate FVL to become non-significant in this

model.

Data availability

The datasets generated and analysed during the current study are available in the Edinburgh

DataShare repository, https://doi.org/10.7488/ds/2598.

Acknowledgements

This project was supported by Agriculture and Food Research Initiative Competitive Grant

no. 2016-67015-24914 from the USDA National Institute of Food and Agriculture

(all authors). RIB's and ADW's contributions were partly funded by the BBSRC Institute

Strategic Funding Grant to The Roslin Institute (BBS/E/D/20002173). The authors would

like to thank the many farm staff and animal caretakers that provided daily care to the birds.

Mention of trade names or commercial products in this publication is solely for the purpose

of providing specific information and does not imply recommendation or endorsement by the

U.S. Department of Agriculture.

References

1. Lessler J, Cummings DA. Mechanistic models of infectious disease and their impact on public health. American journal of epidemiology. 2016 Feb 17;183(5):415-22.

2. Halloran ME, Longini IM, Struchiner CJ, Longini IM. Design and analysis of vaccine studies. New York, NY: Springer; 2010.

3. Read AF, Mackinnon MJ. Pathogen evolution in a vaccinated world. Evolution in health and disease. 2008;2:139-52.

4. Keeling M, Tildesley M, House T, Danon L. The mathematics of vaccination. Math. Today. 2013 Feb;49:40-3.

5. Read AF, Baigent SJ, Powers C, Kgosana LB, Blackwell L, Smith LP, Kennedy DA, Walkden-Brown SW, Nair VK. Imperfect vaccination can enhance the transmission of highly virulent pathogens. PLoS Biology. 2015 Jul 27;13(7):e1002198.

6. Abdelwhab EM, Grund C, Aly MM, Beer M, Harder TC, Hafez HM. Multiple dose vaccination with heterologous H5N2 vaccine: immune response and protection against variant clade 2.2. 1 highly pathogenic avian influenza H5N1 in broiler breeder chickens. Vaccine. 2011 Aug 26;29(37):6219-25.

7. Cano JP, Dee SA, Murtaugh MP, Pijoan C. Impact of a modified-live porcine reproductive and respiratory syndrome virus vaccine intervention on a population of pigs infected with a heterologous isolate. Vaccine. 2007 May 30;25(22):4382-91.

8. Davis NL, Caley IJ, Brown KW, Betts MR, Irlbeck DM, McGrath KM, Connell MJ, Montefiori DC, Frelinger JA, Swanstrom R, Johnson PR. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. Journal of virology. 2000 Jan 1;74(1):371-8.

9. Linhares DC, Cano JP, Wetzell T, Nerem J, Torremorell M, Dee SA. Effect of modified-live porcine reproductive and respiratory syndrome virus (PRRSv) vaccine

on the shedding of wild-type virus from an infected population of growing pigs.

Vaccine. 2012 Jan 5;30(2):407-13.

10. Nodelijk G, De Jong MC, Van Leengoed LA, Wensvoort G, Pol JM, Steverink PJ,

Verheijden JH. A quantitative assessment of the effectiveness of PRRSV vaccination

in pigs under experimental conditions. Vaccine. 2001 Jun 14;19(27):3636-44.

11. Rose N, Renson P, Andraud M, Paboeuf F, Le Potier MF, Bourry O. Porcine

reproductive and respiratory syndrome virus (PRRSv) modified-live vaccine reduces

virus transmission in experimental conditions. Vaccine. 2015 May 15;33(21):2493-9.

12. Trus I, Bonckaert C, van der Meulen K, Nauwynck HJ. Efficacy of an attenuated

European subtype 1 porcine reproductive and respiratory syndrome virus (PRRSV)

vaccine in pigs upon challenge with the East European subtype 3 PRRSV strain Lena.

Vaccine. 2014 May 23;32(25):2995-3003.

13. Churcher TS, Sinden RE, Edwards NJ, Poulton ID, Rampling TW, Brock PM, Griffin

JT, Upton LM, Zakutansky SE, Sala KA, Angrisano F. Probability of transmission of

malaria from mosquito to human is regulated by mosquito parasite density in naive

and vaccinated hosts. PLoS pathogens. 2017 Jan 12;13(1):e1006108.

14. Velthuis AG, De Jong MC, Kamp EM, Stockhofe N, Verheijden JH. Design and

analysis of an Actinobacillus pleuropneumoniae transmission experiment. Preventive

veterinary medicine. 2003 Jul 30;60(1):53-68.

15. Bishop SC, Chesnais J, Stear MJ. Breeding for disease resistance: issues and

opportunities. InProceedings of the 7th World Congress on Genetics Applied to

Livestock Production.'(Ed. INRA)(Institut National de la Recherche Agronomique

(INRA): Montpellier) 2002 Aug 19.

16. Glass EJ. Genetic variation and responses to vaccines. Animal Health Research

Reviews. 2004 Dec;5(2):197-208.

17. Menanteau-Horta AM, Ames TR, Johnson DW, Meiske JC. Effect of maternal

antibody upon vaccination with infectious bovine rhinotracheitis and bovine virus

diarrhea vaccines. Canadian journal of comparative medicine. 1985 Jan;49(1):10.

18. Shim E, Galvani AP. Distinguishing vaccine efficacy and effectiveness. Vaccine.

2012 Oct 19;30(47):6700-5.

19. Haas CN. Microbial dose response modeling: past, present, and future. Environmental

Science & Technology. 2015 Jan 12;49(3):1245-59.

20. Aaby P, Bukh J, Lisse IM, Smits AJ. Overcrowding and intensive exposure as

determinants of measles mortality. American journal of epidemiology. 1984 Jul

1;120(1):49-63.

21. Anderson RM, May RM. Infectious diseases of humans: dynamics and control.

Oxford university press; 1992 Aug 27.

22. Anderson RA, Donnelly CA, Ferguson NM, Woolhouse ME, Watt CJ, Udy HJ,

MaWhinney S, Dunstan SP, Southwood TR, Wilesmith JW, Ryan JB. Transmission

dynamics and epidemiology of BSE in British cattle. Nature. 1996

Aug;382(6594):779.

23. Buchanan RL, Smith JL, Long W. Microbial risk assessment: dose-response relations

and risk characterization. International journal of food microbiology. 2000 Jul

15;58(3):159-72.

24. Havelaar AH, Swart AN. Impact of acquired immunity and dose‐dependent

probability of illness on quantitative microbial risk assessment. Risk Analysis. 2014

Oct;34(10):1807-19.

25. Hornick RB, Music SI, Wenzel R, Cash R, Libonati JP, Snyder MJ, Woodward TE.

The Broad Street pump revisited: response of volunteers to ingested cholera vibrios.

Bulletin of the New York Academy of Medicine. 1971 Oct;47(10):1181.

26. Kothary MH, Babu US. Infective dose of foodborne pathogens in volunteers: a

review. Journal of food safety. 2001 May;21(1):49-68.

27. Powell PC, Lawn AM, Payne LN, Rennie M, Ross LJ. The effect of virus dose on the

development of Marek's disease in two strains of chickens. Avian Pathology. 1980

Oct 1;9(4):567-74.

28. Morrow C, Fehler F. Marek's disease: a worldwide problem. InMarek's disease 2004

Jan 1 (pp. 49-61). Academic Press.

29. Calnek BW, Adldinger HK, Kahn DE. Feather follicle epithelium: a source of

enveloped and infectious cell-free herpesvirus from Marek's disease. Avian diseases.

1970 May 1:219-33.

30. Baaten BJ, Staines KA, Smith LP, Skinner H, Davison TF, Butter C. Early replication

in pulmonary B cells after infection with Marek's disease herpesvirus by the

respiratory route. Viral immunology. 2009 Dec 1;22(6):431-44.

31. Purchase HG. Clinical disease and its economic impact. InMarek's Disease 1985 (pp.

17-42). Springer, Boston, MA.

32. Sharma JM. Laboratory diagnosis. InMarek's Disease 1985 (pp. 151-175). Springer,

Boston, MA.

33. Witter RL, Nazerian K, Purchase HG, Burgoyne GH. Isolation from turkeys of a cell-

associated herpesvtrus antigenically related to Marek's disease virus. American

journal of veterinary research. 1970;31:525-38.

34. Witter RL. The changing landscape of Marek's disease. Avian Pathology. 1998 Apr

1;27(S1):S46-53.

35. Dunn JR, Gimeno IM. Current status of Marek's disease in the United States and

worldwide based on a questionnaire survey. Avian diseases. 2013 Jan 8;57(2s1):483-

90.

36. Witter RL. Increased virulence of Marek's disease virus field isolates. Avian diseases.

1997;41(1):149-63.

37. Bacon LD, Hunt HD, Cheng HH. A review of the development of chicken lines to

resolve genes determining resistance to diseases. Poultry science. 2000 Aug

1;79(8):1082-93.

38. Witter RL. Protective efficacy of Marek's disease vaccines. In Marek's Disease 2001

(pp. 57-90). Springer, Berlin, Heidelberg.

39. Dunn JR, Witter RL, Silva RF, Lee LF, Finlay J, Marker BA, Kaneene JB, Fulton

RM, Fitzgerald SD. The effect of the time interval between exposures on the

susceptibility of chickens to superinfection with Marek's disease virus. Avian

diseases. 2010 Sep;54(3):1038-49.

40. Cortes AL, Montiel ER, Lemiere S, Gimeno IM. Comparison of blood and feather

pulp samples for the diagnosis of Marek's disease and for monitoring Marek's disease

vaccination by real time-PCR. Avian diseases. 2011 Jun;55(2):302-10.

41. Kennedy DA, Dunn PA, Read AF. Modeling Marek's disease virus transmission: A

framework for evaluating the impact of farming practices and evolution. Epidemics.

2018 Jun 1;23:85-95.

42. Calnek BW, Hitchner SB. Localization of viral antigen in chickens infected with

Marek's disease herpesvirus. Journal of the National Cancer Institute. 1969 Oct

1;43(4):935-49.

43. Meeusen EN, Walker J, Peters A, Pastoret PP, Jungersen G. Current status of

veterinary vaccines. Clinical microbiology reviews. 2007 Jul 1;20(3):489-510.

44. Gandon S, Mackinnon MJ, Nee S, Read AF. Imperfect vaccines and the evolution of

pathogen virulence. Nature. 2001 Dec;414(6865):751.

45. McLean AR, Blower SM. Imperfect vaccines and herd immunity to HIV. Proceedings

of the Royal Society of London. Series B: Biological Sciences. 1993 Jul

22;253(1336):9-13.

46. Poland GA, Ovsyannikova IG, Jacobson RM, Smith DI. Heterogeneity in vaccine

immune response: the role of immunogenetics and the emerging field of vaccinomics.

Clinical Pharmacology & Therapeutics. 2007 Dec;82(6):653-64.

47. Anderson RM, May RM. Vaccination and herd immunity to infectious diseases.

Nature. 1985 Nov;318(6044):323.

48. Bitsouni V, Lycett S, Opriessnig T, Doeschl-Wilson A. Predicting vaccine

effectiveness in livestock populations: a theoretical framework applied to PRRS virus

infections in pigs. 2019PLoS ONE. Accepted.

49. Doeschl-Wilson AB, Davidson R, Conington J, Roughsedge T, Hutchings MR,

Villanueva B. Implications of host genetic variation on the risk and prevalence of

infectious diseases transmitted through the environment. Genetics. 2011 Jul

1;188(3):683-93.

50. Gomes MG, Lipsitch M, Wargo AR, Kurath G, Rebelo C, Medley GF, Coutinho A. A

missing dimension in measures of vaccination impacts. PLoS pathogens. 2014 Mar

6;10(3):e1003849.

51. Gomes MG, Gordon SB, Lalloo DG. Clinical trials: The mathematics of falling

vaccine efficacy with rising disease incidence. Vaccine. 2016 Jun 8;34(27):3007.

52. Crow JF, Kimura M. An introduction to population genetics theory. An introduction

to population genetics theory. 1970.

53. Hunt HD, Dunn JR. The influence of host genetics on Marek's disease virus

evolution. Avian diseases. 2013 Jun 15;57(2s1):474-82.

54. Bacon LD, Hunt HD, Cheng HH. Genetic resistance to Marek's disease. In Marek's
Disease 2001 (pp. 121-141). Springer, Berlin, Heidelberg.

55. Bishop SC, Woolliams JA. Genomics and disease resistance studies in livestock.
Livestock science. 2014 Aug 1;166:190-8.

56. Thornton PK. Livestock production: recent trends, future prospects. Philosophical
Transactions of the Royal Society B: Biological Sciences. 2010 Sep
27;365(1554):2853-67.

57. Bacon LD, Hunt HD, Cheng HH. A review of the development of chicken lines to
resolve genes determining resistance to diseases. Poultry science. 2000 Aug
1;79(8):1082-93.

58. Dunn JR, Silva RF. Ability of MEQ-deleted MDV vaccine candidates to adversely
affect lymphoid organs and chicken weight gain. Avian diseases. 2012 Sep;56(3):494-
500.

59. R Core Team (2019). R: A language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-
project.org/.

60. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using
lme4. Journal of Statistical Software. 2015 June 30; 67(1):1-48.
doi:10.18637/jss.v067.i01.

61. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model.
Springer Science & Business Media; 2013 Nov 11.

62. Christensen, RHB. ordinal - Regression Models for Ordinal Data. R package version
2019.4-25. http://www.cran.r-project.org/package=ordinal/.

63. Judd CM, Kenny DA. Process analysis: Estimating mediation in treatment
evaluations. Evaluation review. 1981 Oct;5(5):602-19.

64. McCune B, Mefford MJ. PC-ORD: multivariate analysis of ecological data: version 7

for Windows. MjM software design. 2016.

Author contributions

JRD led project conceptualization, experimental design and funding acquisition, alongside

ADW, HHC and OA. Experimentation and data curation were carried out by JRD (lead),

JKM and HHC. RIB took the lead in statistical analysis with contributions from MCT and

ADW. RIB led interpretation of results and manuscript writing, alongside ADW, JRD, HHC,

MCT. All authors contributed to reviewing and editing the manuscript.

Competing interests

The authors declare no competing interests.

Materials & Correspondence

Requests for physical materials and raw data should be addressed to JRD. Requests for

analysis scripts and outputs should be addressed to ADW or RIB.